GlassScriptPhysician profile
Kung-Ching Lin
NPI 1326279753
$6,242.42
in general payments reported to CMS, 2019-2025
16 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $458 · 2021: $910 · 2022: $1,382 · 2023: $850 · 2024: $795 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,293.13 | 2019-2025 | Vemlidy |
| Amgen INC. | $1,634.27 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $660.96 | 2019-2022 | |
| Novo Nordisk INC | $449.88 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.90 | 2019-2024 | Jardiance |
| Abbvie INC. | $265.08 | 2022-2025 | |
| Axsome Therapeutics, INC. | $262.50 | 2024 | Auvelity |
| Lilly USA, LLC | $97.86 | 2019-2023 | Mounjaro |
| Allergan, INC. | $52.70 | 2019 | |
| Hologic Sales and Service, LLC | $29.77 | 2024 | Biozorb, Celero-12, Localizer |
| Phathom Pharmaceuticals, INC. | $27.67 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $25.47 | 2022 | |
| Agios Pharmaceuticals, INC. | $23.33 | 2025 | Pyrukynd |
| Esperion Therapeutics, INC. | $20.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.27 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kung-Ching Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.